The Food and Drug Administration approved osimertinib, or Tagrisso, from AstraZeneca Pharmaceuticals for adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC, whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca says Fasenra recommended for approval in EU by CHMP
- AstraZeneca: Datopotamab deruxtecan didn’t achieve statistical significance
- AstraZeneca confirms FluMist approved for self-administration in U.S.
- FDA approves AstraZeneca’s FluMist for self- or caregiver-administration
- AIM reports preliminary data in Phase 1b/2 study of Ampligen, Imfinzi
Questions or Comments about the article? Write to editor@tipranks.com